EyeGate Pharmaceuticals
EyeGate Pharmaceuticals

EyeGate Pharmaceuticals

DR33Ahrefs DR: 33/100. Below median. Measured by Ahrefs. Median 44.Agent39Agent Readiness: 39/100. Below median. Measured by StartupHub.ai. Median 41.Speed57Site Speed: 57/100. Below median. Measured by Google PageSpeed. Median 62.

Clinical-stage specialty pharmaceutical company developing therapeutics and drug delivery systems for ophthalmic diseases.

Website
2000ActiveWaltham, United States

About

EyeGate Pharmaceuticals was a clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The company's lead product candidate was EGP-437, which utilized a proprietary iontophoretic drug delivery system. EyeGate underwent a name change to Kiora Pharmaceuticals in November 2021.

Key facts

At-a-glance profile data

Website
kiorapharma.com
Headquarters
Waltham, United States
Founded
2000
Total funding
$45M (Debt)
Business model
B2B | B2C | B2B2C | B2G

Funding rounds

Funding rounds raised by EyeGate Pharmaceuticals
DateRoundAmountLead investors
27 Jun 2016Debt$4M-
19 Feb 2015IPO$4M-
8 Jan 2010Series D$23M-
12 Mar 2008Series C$15M-

Tech stack

Detected on kiorapharma.com, last scanned 3 Sept 2026. Run your own scan

Compliance
GDPR, CCPA
Analytics
Google Analytics 4, Google Tag Manager
SEO
Yoast SEO
CMS / Builders
WordPress
CDN
Cloudflare
Email provider
Microsoft 365
Add first review

Frequently asked

How much funding has EyeGate Pharmaceuticals raised?

EyeGate Pharmaceuticals has raised a total of $45M in funding. The most recent round on record is Debt.